Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
250.68
+6.14 (2.51%)
At close: Aug 31, 2026, 4:00 PM EDT
250.68
0.00 (0.00%)
Pre-market: Sep 1, 2026, 8:16 AM EDT
Jazz Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,601 | 4,268 | 4,069 | 3,834 | 3,659 | 3,094 | |
Revenue Growth | 12.59% | 4.88% | 6.12% | 4.78% | 18.26% | 30.91% |
Cost of Revenue | 397.85 | 355.35 | 310.7 | 284.13 | 267.13 | 217.68 |
Gross Profit | 4,203 | 3,912 | 3,758 | 3,550 | 3,392 | 2,877 |
Selling, General & Admin | 1,540 | 1,498 | 1,416 | 1,307 | 1,399 | 1,399 |
Research & Development | 774.39 | 741.49 | 851.06 | 818.39 | 555.41 | 476.33 |
Amortization of Goodwill & Intangibles | 680.46 | 654.66 | 627.31 | 608.28 | 599.17 | 525.77 |
Operating Expenses | 2,994 | 2,894 | 2,894 | 2,734 | 2,553 | 2,401 |
Operating Income | 1,209 | 1,018 | 864.14 | 816.23 | 839.14 | 475.26 |
Interest Expense | -258.65 | -280.85 | -344.4 | -354.54 | -299.74 | -280.57 |
Interest & Investment Income | 87.7 | 85.8 | 106.3 | 65.1 | 11.5 | 1.8 |
Earnings From Equity Investments | -0.23 | -0.73 | -1.66 | -3.01 | -9.92 | -0.71 |
Currency Exchange Gain (Loss) | 1.83 | -2.57 | -8.18 | 8.79 | -19.01 | -4.35 |
EBT Excluding Unusual Items | 1,163 | 819.72 | 616.21 | 532.57 | 521.97 | 191.43 |
Merger & Restructuring Charges | -164.05 | -176.95 | -137.51 | -156.95 | -326.88 | -304.99 |
Asset Writedown | - | - | - | -61.7 | -133.65 | - |
Legal Settlements | -151.5 | -323.5 | - | - | - | - |
Pretax Income | 727.51 | -628.59 | 468.69 | 294.92 | -382.71 | -113.55 |
Income Tax Expense | -213.24 | -272.44 | -91.43 | -119.91 | -158.65 | 216.12 |
Earnings From Continuing Operations | 940.75 | -356.15 | 560.12 | 414.83 | -224.06 | -329.67 |
Net Income | 940.75 | -356.15 | 560.12 | 414.83 | -224.06 | -329.67 |
Net Income to Common | 940.75 | -356.15 | 560.12 | 414.83 | -224.06 | -329.67 |
Net Income Growth | - | - | 35.02% | - | - | - |
Shares Outstanding (Basic) | 62 | 61 | 62 | 63 | 63 | 60 |
Shares Outstanding (Diluted) | 64 | 61 | 66 | 72 | 63 | 60 |
Shares Change | 5.40% | -7.61% | -8.41% | 15.23% | 4.77% | 5.62% |
EPS (Basic) | 15.25 | -5.84 | 9.06 | 6.55 | -3.58 | -5.52 |
EPS (Diluted) | 14.63 | -5.84 | 8.65 | 6.10 | -3.58 | -5.52 |
EPS Growth | - | - | 41.75% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1,591 | 1,297 | 1,358 | 1,068 | 1,243 | 750.87 |
Free Cash Flow Per Share | 24.74 | 21.27 | 20.57 | 14.82 | 19.87 | 12.58 |
Gross Margin | 91.35% | 91.67% | 92.36% | 92.59% | 92.70% | 92.97% |
Operating Margin | 26.28% | 23.86% | 21.24% | 21.29% | 22.93% | 15.36% |
Profit Margin | 20.45% | -8.34% | 13.77% | 10.82% | -6.12% | -10.65% |
Free Cash Flow Margin | 34.58% | 30.39% | 33.37% | 27.86% | 33.97% | 24.27% |
EBITDA | 1,927 | 1,714 | 1,524 | 1,455 | 1,469 | 1,028 |
EBITDA Margin | 41.88% | 40.17% | 37.46% | 37.95% | 40.13% | 33.22% |
D&A For EBITDA | 718 | 696.3 | 660.07 | 638.7 | 629.47 | 552.48 |
EBIT | 1,209 | 1,018 | 864.14 | 816.23 | 839.14 | 475.26 |
EBIT Margin | 26.28% | 23.86% | 21.24% | 21.29% | 22.93% | 15.36% |
Revenue as Reported | 4,601 | 4,268 | 4,069 | 3,834 | 3,659 | 3,094 |
Advertising Expenses | - | 105.6 | 107.4 | 92.2 | 108.8 | 161.5 |